FDA Designates Magnus Medical’s Depression Therapy a Breakthrough Device

November 4, 2021

Magnus Medical has been granted the FDA’s Breakthrough Device designation for its Magnus System for treatment of depression.

The device is an individualized, rapid-acting, neurostimulation technology designed to treat major depressive disorder in people who have not improved sufficiently from antidepressant medication or other treatments.  

The Magnus System is based on technology licensed exclusively to the Burlingame, Calif.-company by Stanford University.

View today's stories